The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. - Wikidata - awgldk - TriplyDB

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

http://www.wikidata.org/entity/Q35004491

about

Adverse events associated with hormonal therapy for prostate cancer Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?Loss of osteoprotegerin expression in the inner ear causes degeneration of the cochlear nerve and sensorineural hearing loss.Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions.Bone health in nonmetastatic prostate cancer: what's the big deal?MAPK11 in breast cancer cells enhances osteoclastogenesis and bone resorption.Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis.Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US.Local application of ibandronate/gelatin sponge improves osteotomy healing in rabbits.Injectable bisphosphonates in the treatment of postmenopausal osteoporosis.Bony metastases: assessing response to therapy with whole-body diffusion MRI.Bone-targeted agents in the treatment of lung cancer.Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid.Bone loss after allogeneic haematopoietic stem cell transplantation: a pilot study on the use of zoledronic Acid.Mechanisms of cancer metastasis to the bone.The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 2: Clinical studies and economic analyses.Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art Zoledronic acid in the management of metastatic bone disease.Breaking down bone: new insight into site-specific mechanisms of breast cancer osteolysis mediated by metalloproteinases.Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.Androgen deprivation and bone.New role for an established drug? Bisphosphonates as potential anticancer agents.Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy.CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.Well-differentiated hand liposarcoma with bone metastases treated successfully with zoledronic Acid.Pamidronate disodium for palliative therapy of feline bone-invasive tumors.Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease.Local application of zoledronic acid incorporated in a poly(D,L-lactide)-coated implant accelerates fracture healing in rats.Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.Therapy monitoring of skeletal metastases with whole-body diffusion MRI.Emerging and Established Models of Bone Metastasis.

P2860

Q24548201-F382D826-34E9-4A01-8C27-D0A3ABF16C28 Q28068956-A5B75244-CB35-4606-A993-36AD96E07542 Q30433880-54C65AF3-F863-47FC-928C-610C26A534BF Q33432776-2FEEAD86-9730-471D-879C-4617089AC082 Q33705995-E51548B5-57B5-4772-AF0B-DC1DB39F26E2 Q34111621-5E20C875-E5CE-4751-99AA-518B574A2BE3 Q34602557-80B78DA7-79FF-42FF-9F14-D25EDF924D86 Q35147059-712EF30D-EB55-43B8-8F09-CB0723996110 Q35161962-35061A32-8CA4-4AEC-A8E2-1C7C5077BE24 Q35581742-C303CED0-F47C-42D9-94E2-DCA023453D16 Q35602572-CDBD0FED-5CAA-48A2-BE66-7EFE75472586 Q35697593-3C2A41F5-E24F-4A9E-8A22-39E3F36089C9 Q35780792-CCD0098F-0709-41E3-9375-3A0411E8B7E8 Q35865726-AC3F697E-B329-420F-B044-0ECFD959F985 Q35895664-B57FC3B1-3923-40B5-A526-3366EC0EB540 Q36027386-725BB748-A5E3-435C-93F4-6AD8DF83138D Q36073657-88E9BA6B-42E8-4D91-AE9F-E2DC57C86C66 Q36073662-05884D55-5105-46DC-BA3A-3BAC6EBF1ADB Q36080739-87A367B6-A7D3-4682-8636-1EA4DAA3DC5A Q36278556-2268D40D-A643-467D-A266-5A66B08DF6C5 Q36708315-750D3F30-BC00-435C-87F6-C4ED0C546357 Q37362838-5AB0473A-B8D0-4531-A750-71C6573AD4EA Q37702066-4CD1A57C-F786-47FA-8EBD-482BB87F0C38 Q37812612-57BA745A-D175-441A-BE0C-F8CA6388BA6D Q37821350-18AE60F3-AC1D-45E3-86F2-55B1C0B41556 Q37923744-9328BB95-8D2B-45ED-B3EA-F400D7F37164 Q37966693-4419F9BA-7753-4E12-9BDA-6F36137A8055 Q38581768-625AC4D2-9744-4C1A-B5B3-29EF1EF3450C Q39174534-0C61C9B2-4EE2-421A-B551-C3656748A85F Q39254815-E0D542B9-D4E1-4F68-8031-D4F4EE8FB741 Q41239033-245047E8-29AB-4969-8578-C223E6CA75C4 Q42225343-7FD6A1E5-E11D-46E5-AF5E-DE173B2D089B Q43677840-A08A6158-246F-42E8-8BB9-CEDA9E1A5597 Q47733526-DC6A6F4D-7E1C-4EAB-8590-D65D0790AB2B Q51114179-8112D5B2-0049-4BAF-828C-0ACA8361E446 Q55515343-94DB16C1-5FDE-4776-9BB7-88F8F8F9732D

P2860

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.

http://www.wikidata.org/entity/Q35004491

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@ast

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@en

type

label

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@ast

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@en

prefLabel

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@ast

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@en

P1433

Q35004491-90C18346-404F-4E69-8E21-FFB8CD717AA9

P1476

Q35004491-AACD0423-9906-4C64-9B44-E4C7F5FC8790

P2093

Q35004491-1D8EAD00-85A6-4F47-B84E-204C7E6B0677

Q35004491-6E79F4D3-445B-4849-8D1A-BE1A781E6396

Q35004491-8E995BEE-EDE7-4059-A487-6B5B111CC3B1

Q35004491-9032B857-1095-4988-A1DE-EC173489F44E

Q35004491-973DBFA8-85FB-450D-B3EF-5B916B02071A

Q35004491-B021A64C-DDD2-442A-9FF5-978B1928AEA6

Q35004491-B28DDFDE-CB8F-47FD-AFE6-3B3BCCF280DE

Q35004491-B653FA74-0D39-492F-A7C8-27A50E516BA1

Q35004491-B7C69137-1785-4EA8-9F51-A3FF2816E56A

Q35004491-BB186D87-E4A2-4BAB-B3FE-9E49F841EB00

P2860

Q35004491-00693EFC-657D-49C0-B6EC-B724789787E9

Q35004491-17C8CBC7-6CE7-4B5B-8D55-4D5D9AB75270

Q35004491-3D1FA59D-34BE-4116-B9A9-F4EA1E44956F

Q35004491-48AE07BC-5B32-4749-BC80-AACD8623CCFC

Q35004491-54C461B0-116E-4BA9-8C2B-998EC15451CE

Q35004491-714CBFF5-027D-46CD-B58D-C21603FC29EA

Q35004491-785D61B6-52AD-4B14-ACE8-A55BC9E34CAA

Q35004491-91C44B72-1762-4A96-8B29-0B3B2C4E483F

Q35004491-927DD52E-4963-4C61-BA4D-DB152455A353

Q35004491-A2D06437-14CB-4844-931A-AFC356B7FD9C

P304

Q35004491-B2EC0430-4A0E-4B30-99AA-71B6AEB4915A

P31

Q35004491-6EB718F6-A0AE-496E-9C29-493AB28F07D0

P356

Q35004491-45DE0C2B-0189-48A9-B115-DCC01BCA3122

P478

Q35004491-AF139D4B-F8EE-43FD-A2F7-F2BA50B3FCEC

P577

Q35004491-41435376-237E-48A9-979D-601A8AF8EB1C

P698

Q35004491-825BE0A9-D56B-4DD7-82E8-8E757C135ECE

P356

P1433

Cancer Investigation

P1476

The new bisphosphonate, Zometa ...... : a comparison to pamidronate.

@en

P2093

Allan Lipton

http://www.w3.org/2001/XMLSchema#string

D Gleason

http://www.w3.org/2001/XMLSchema#string

David Gordon

http://www.w3.org/2001/XMLSchema#string

Dirk Reitsma

http://www.w3.org/2001/XMLSchema#string

E Small

http://www.w3.org/2001/XMLSchema#string

Fred Saad

http://www.w3.org/2001/XMLSchema#string

John Seaman

http://www.w3.org/2001/XMLSchema#string

Lee Rosen

http://www.w3.org/2001/XMLSchema#string

M Ortu Kowalski

http://www.w3.org/2001/XMLSchema#string

M Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of painful prostatic bone metastases with oral etidronate disodium.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

Concomitant i.v. and oral clodronate in the relief of bone pain--a double-blind placebo-controlled study in patients with prostate cancer

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer.

The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double-blind randomised placebo-controlled study.

Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.

Spread of prostatic cancer to bone.

Stimulation of bone formation in vitro and in rodents by statins.

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.

P304

45-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1081/CNV-120014886

http://www.w3.org/2001/XMLSchema#string

P478

20 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12442349

http://www.w3.org/2001/XMLSchema#string